Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Erasca Inc | ERAS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.88 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.88 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.51 - 3.375 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.88 | USD |
Erasca Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 284.04M | 151.09M | - | 0 | -125.04M | -0.83 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Erasca News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ERAS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.82 | 1.9735 | 1.74 | 1.84 | 504,082 | 0.06 | 3.30% |
| 1 Month | 2.42 | 2.588 | 1.74 | 2.08 | 791,651 | -0.54 | -22.31% |
| 3 Months | 1.67 | 2.655 | 1.64 | 2.14 | 816,797 | 0.21 | 12.57% |
| 6 Months | 2.29 | 2.655 | 1.51 | 2.00 | 960,606 | -0.41 | -17.90% |
| 1 Year | 2.70 | 3.375 | 1.51 | 2.25 | 799,234 | -0.82 | -30.37% |
| 3 Years | 15.90 | 24.47 | 1.51 | 6.03 | 724,171 | -14.02 | -88.18% |
| 5 Years | 15.90 | 24.47 | 1.51 | 6.03 | 724,171 | -14.02 | -88.18% |
Erasca Description
| Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. |
